Companies / ALA

AROVELLA THERAPEUTICS LIMITED

ASX:ALAPharmaceuticals, Biotechnology & Life Sciences
1.21B shares on issueASX (delayed) · as of 28 July 2026$0.064price · delayed$77.4Mmarket cap · indicative
C
Dilution grade

3 cash raises in 24 months; runway 4–8 quarters; options/rights overhang 29% of shares

Cash runway5.1 quarters of funding
Share-count growth (24m)14.9%
Raise cadence (24m)3 cash raises
Options & rights overhang28.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

AROVELLA THERAPEUTICS LIMITED's ordinary share count grew 14.9% between July 2024 and June 2026 to 1.21B shares. The company completed three capital raises within the 24‑month window for total disclosed proceeds of A$15.8M, most recently raising A$15.0M in February 2025. Options and rights on issue could convert into 347M new shares, equal to 28.7% of the current share count, with 0% in the money and the nearest expiry in May 2027. At the June 2026 quarter the company reported A$13.5M in cash, representing 5.1 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
28.7%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
5.1 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.21B per ASX (delayed) (28 July 2026).
1.09B1.13B1.18BDec 24Sept 25July 26Cash raise · 5 Feb 2025Cash raise · 7 Jan 2025

Cash runway

5.1 qtrs
More than four quarters of funding at the recent spend rate.
$13.5M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
29 June 20262A · quoted issueALA : ORDINARY FULLY PAID1.21BAppendix 2A
29 June 20263H · cancellationALA : ORDINARY FULLY PAID1.21BAppendix 3H
25 May 20263H · cancellationALA : ORDINARY FULLY PAID1.21BAppendix 3H
7 May 20263H · cancellationALA : ORDINARY FULLY PAID1.21BAppendix 3H
26 Apr 20263G · unquotedALA : ORDINARY FULLY PAID1.21BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 0 in the last 12 months

$15.0M
Capital raise
5 Feb 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

28.7%
Total overhang · of current shares
0.0%
In the money · at current price
346.8M
Potential new shares
May 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
9 June 2026David John WilliamsBuy200k—$13k3Y notice
24 Nov 2025Elizabeth StonerOther1.2M——3Y notice
12 Nov 2025Debora BartonBuy1.0M1.4M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
29 June 2026Notice under Section 708A
29 June 2026Notification of cessation of securities - ALA
29 June 2026Application for quotation of securities - ALA
24 June 2026First-In-Human Trial
9 June 2026Change of Director's Interest Notice
9 June 2026Turtle to Clinical Advisory Board&Fiorenza Lead Investigator
25 May 2026Notification of cessation of securities - ALA
7 May 2026Notification of cessation of securities - ALA
7 May 2026Final Director's Interest Notice x4
6 May 2026Arovella Presents at ISCT Conference in Dublin
6 May 2026$PArovella Appoints Acting CEO
4 May 2026$PBoard Refresh and CEO Resignation
1 May 2026Initial Director's Interest Notice x4
28 Apr 2026Appointment of 4x Non-Executive Directors
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
26 Apr 2026Notification regarding unquoted securities - ALA
22 Apr 2026Notice Received Under Section 249D Withdrawn
22 Apr 2026Proposed issue of securities - ALA
22 Apr 2026Update Regarding Section 249D Notice

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.